Company Analysis Global Blood Therapeutics, Inc.
1. Summary
Advantages
- Price (67.5 $) is less than fair price (73.7 $)
- The stock's return over the last year (0%) is higher than the sector average (-48.03%).
Disadvantages
- Dividends (0%) are below the sector average (0.53%).
- Current debt level 75.64% has increased over 5 years from 21.23%.
- The company's current efficiency (ROE=-204.89%) is lower than the sector average (ROE=104.24%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Global Blood Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -0.1% | -2.3% |
| 90 days | 0% | 11.2% | 0.9% |
| 1 year | 0% | -48% | 16.4% |
GBT vs Sector: Global Blood Therapeutics, Inc. has outperformed the "Healthcare" sector by 48.03% over the past year.
GBT vs Market: Global Blood Therapeutics, Inc. has significantly underperformed the market by -16.37% over the past year.
Stable price: GBT is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GBT with weekly volatility of 0% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (67.5 $) is lower than the fair price (73.7 $).
Price not significantly lower than the fair price: The current price (67.5 $) is slightly lower than the fair price by 9.2%.
5.2. P/E
P/E vs Sector: The company's P/E (-14.33) is lower than that of the sector as a whole (36.09).
P/E vs Market: The company's P/E (-14.33) is higher than that of the market as a whole (-104.3).
5.3. P/BV
P/BV vs Sector: The company's P/BV (39.05) is lower than that of the sector as a whole (254.48).
P/BV vs Market: The company's P/BV (39.05) is lower than that of the market as a whole (72.17).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (18.8) is lower than that of the sector as a whole (127.4).
P/S vs Market: The company's P/S indicator (18.8) is lower than that of the market as a whole (114).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-1.38) is higher than that of the sector as a whole (-27.32).
EV/Ebitda vs Market: The company's EV/Ebitda (-1.38) is higher than that of the market as a whole (-78.04).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 1.28% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (1.28%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (435.8%).
6.4. ROE
ROE vs Sector: The company's ROE (-204.89%) is lower than that of the sector as a whole (104.24%).
ROE vs Market: The company's ROE (-204.89%) is lower than that of the market as a whole (-6.22%).
6.6. ROA
ROA vs Sector: The company's ROA (-35.64%) is lower than that of the sector as a whole (-2.25%).
ROA vs Market: The company's ROA (-35.64%) is lower than that of the market as a whole (38.45%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-42.95%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (-42.95%) is lower than that of the market as a whole (9.79%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.53%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 27.09.2022 | Choi Jung See Remarks |
Purchase | 7.04 | 700 403 | 99 489 |
| 27.09.2022 | LOVE TED W President and CEO |
Purchase | 16.4 | 299 972 | 18 291 |
| 27.09.2022 | Habibizad Nazila See Remarks |
Purchase | 19.17 | 570 403 | 29 755 |
| 27.09.2022 | Farrow Jeffrey S Chief Financial Officer |
Purchase | 16.4 | 387 909 | 23 653 |
| 01.09.2022 | Farrow Jeffrey S Chief Financial Officer |
Sale | 68 | 2 137 990 | 31 441 |
Based on sources: porti.ru
